MaxCyte (MXCT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

MXCT Stock Forecast

MaxCyte stock forecast is as follows: an average price target of $8.00 (represents a 125.35% upside from MXCT’s last price of $3.55) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

MXCT Price Target

The average price target for MaxCyte (MXCT) is $8.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 125.35% upside from MXCT's last price of $3.55.

MXCT Analyst Ratings

Buy

According to 3 Wall Street analysts, MaxCyte's rating consensus is 'Buy'. The analyst rating breakdown for MXCT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

MaxCyte Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 13, 2024	Mark Massaro	BTIG	$8.00	$4.16	92.31%	125.35%
Aug 14, 2022	Mark Massaro	BTIG	$11.00	$5.87	87.39%	209.86%

Row per page

Go to

The latest MaxCyte stock forecast, released on Mar 13, 2024 by Mark Massaro from BTIG, set a price target of $8.00, which represents a 92.31% increase from the stock price at the time of the forecast ($4.16), and a 125.35% increase from MXCT last price ($3.55).

MaxCyte Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$8.00
Last Closing Price	$3.55	$3.55	$3.55
Upside/Downside	-100.00%	-100.00%	125.35%

In the current month, the average price target of MaxCyte stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MaxCyte's last price of $3.55. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 10, 2024	Deutsche Bank	Hold	Buy	Upgrade
Sep 24, 2024	Cowen & Co.	Buy	Buy	Hold
May 03, 2024	Deutsche Bank	-	Hold	Initialise
Mar 13, 2024	BTIG	Buy	Buy	Hold
Aug 14, 2022	BTIG	Buy	Buy	Hold

Row per page

Go to

MaxCyte's last stock rating was published by Deutsche Bank on Oct 10, 2024. The company Upgrade its MXCT rating from "Hold" to "Buy".

MaxCyte Financial Forecast

MaxCyte Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Jun 20	Mar 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$15.66M	$8.00B	$9.04B	$8.58M	$12.42M	$10.64M	$9.61M	$11.59M	$10.15M	$10.14M	$7.11M	$5.15M	-
Avg Forecast	$14.20M	$13.97M	$13.96M	$13.42M	$12.77M	$11.86M	$10.59M	$9.79M	$7.76M	$7.46M	$7.97M	$7.51M	$13.44M	$8.87M	$10.66M	$8.27M	$12.40M	$10.43M	$9.23M	$8.46M	$9.56M	$7.28M	$5.79M	$13.39M	$8.40M
High Forecast	$14.60M	$14.37M	$14.36M	$13.80M	$13.14M	$12.19M	$10.90M	$10.07M	$7.81M	$7.46M	$7.97M	$7.51M	$15.45M	$9.17M	$10.96M	$8.51M	$12.75M	$10.43M	$9.23M	$8.46M	$9.56M	$7.28M	$5.79M	$13.39M	$8.40M
Low Forecast	$13.76M	$13.54M	$13.53M	$13.00M	$12.38M	$11.49M	$10.26M	$9.49M	$7.71M	$7.46M	$7.97M	$7.51M	$11.44M	$8.57M	$10.33M	$8.02M	$12.01M	$10.43M	$9.23M	$8.46M	$9.56M	$7.28M	$5.79M	$13.39M	$8.40M
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.17%	902.42%	848.41%	1.04%	1.00%	1.02%	1.04%	1.37%	1.06%	1.39%	1.23%	0.38%	-

MaxCyte's average Quarter revenue forecast for Mar 24 based on 2 analysts is $7.51M, with a low forecast of $7.51M, and a high forecast of $7.51M. MXCT's average Quarter revenue forecast represents a -52.09% decrease compared to the company's last Quarter revenue of $15.66M (Dec 23).

MaxCyte EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Jun 20	Mar 20
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$15.66M	$-12.13B	$-11.12B	$-12.22M	$-3.88M	$-5.61M	$-7.71M	$-3.58M	$-3.45M	$-2.03M	$-4.41M	$-2.84M	-
Avg Forecast	$-8.16M	$-8.03M	$-8.03M	$-7.72M	$-7.35M	$-6.82M	$-6.09M	$-5.63M	$-4.46M	$-4.29M	$-4.58M	$-4.32M	$-7.73M	$-5.10M	$-6.13M	$-4.76M	$-7.13M	$-6.00M	$-5.31M	$-4.87M	$-5.50M	$-2.55M	$-3.33M	$-7.70M	$-4.83M
High Forecast	$-7.91M	$-7.78M	$-7.78M	$-7.48M	$-7.12M	$-6.61M	$-5.90M	$-5.46M	$-4.43M	$-4.29M	$-4.58M	$-4.32M	$-6.58M	$-4.93M	$-5.94M	$-4.61M	$-6.91M	$-6.00M	$-5.31M	$-4.87M	$-5.50M	$-2.04M	$-3.33M	$-7.70M	$-4.83M
Low Forecast	$-8.40M	$-8.26M	$-8.26M	$-7.94M	$-7.56M	$-7.01M	$-6.27M	$-5.79M	$-4.49M	$-4.29M	$-4.58M	$-4.32M	$-8.88M	$-5.27M	$-6.30M	$-4.89M	$-7.33M	$-6.00M	$-5.31M	$-4.87M	$-5.50M	$-3.06M	$-3.33M	$-7.70M	$-4.83M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-2.03%	2377.37%	1814.01%	2.57%	0.54%	0.93%	1.45%	0.74%	0.63%	0.79%	1.33%	0.37%	-

2 analysts predict MXCT's average Quarter EBITDA for Mar 24 to be $-4.32M, with a high of $-4.32M and a low of $-4.32M. This is -127.55% lower than MaxCyte's previous annual EBITDA (Dec 23) of $15.66M.

MaxCyte Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Jun 20	Mar 20
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	$-11.25B	$-10.51B	$-8.59M	$-2.87M	$-5.16M	$-7.78M	$-3.98M	$-4.87M	$-2.68M	$-4.42M	$-3.00M	-
Avg Forecast	$-10.51M	$-10.51M	$-10.51M	$-10.51M	$-10.51M	$-9.99M	$-11.04M	$-11.56M	$-12.61M	$-12.61M	$-12.96M	$-13.14M	$-6.68M	$-10.61M	$-10.09M	$-11.77M	$-8.14M	$-9.42M	$-7.95M	$-6.91M	$-6.07M	$-3.38M	$-7.06M	-	-
High Forecast	$-10.09M	$-10.09M	$-10.09M	$-10.09M	$-10.09M	$-9.58M	$-10.59M	$-11.09M	$-10.81M	$-12.10M	$-12.44M	$-12.61M	$-6.46M	$-10.18M	$-9.68M	$-11.30M	$-7.81M	$-9.42M	$-7.95M	$-6.91M	$-6.07M	$-2.70M	$-7.06M	-	-
Low Forecast	$-10.90M	$-10.90M	$-10.90M	$-10.90M	$-10.90M	$-10.36M	$-11.45M	$-11.99M	$-13.51M	$-13.08M	$-13.44M	$-13.63M	$-6.89M	$-11.00M	$-10.47M	$-12.21M	$-8.45M	$-9.42M	$-7.95M	$-6.91M	$-6.07M	$-4.05M	$-7.06M	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1060.62%	1041.75%	0.73%	0.35%	0.55%	0.98%	0.58%	0.80%	0.79%	0.63%	-	-

MaxCyte's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MXCT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

MaxCyte SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Jun 20	Mar 20
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	$13.87B	$14.10B	$13.79M	$11.03M	$10.95M	$12.03M	$10.47M	$10.06M	$8.86M	$7.54M	$3.44M	-
Avg Forecast	$13.07M	$12.86M	$12.85M	$12.35M	$11.76M	$10.91M	$9.75M	$9.01M	$7.14M	$6.87M	$7.33M	$6.91M	$12.37M	$8.17M	$9.81M	$7.62M	$11.41M	$9.60M	$8.50M	$7.79M	$8.80M	$6.70M	$5.33M	$12.32M	$7.73M
High Forecast	$13.44M	$13.23M	$13.22M	$12.70M	$12.09M	$11.23M	$10.03M	$9.27M	$7.19M	$6.87M	$7.33M	$6.91M	$14.22M	$8.44M	$10.09M	$7.83M	$11.74M	$9.60M	$8.50M	$7.79M	$8.80M	$6.70M	$5.33M	$12.32M	$7.73M
Low Forecast	$12.66M	$12.46M	$12.45M	$11.97M	$11.39M	$10.57M	$9.45M	$8.73M	$7.09M	$6.86M	$7.33M	$6.91M	$10.53M	$7.89M	$9.51M	$7.38M	$11.06M	$9.60M	$8.50M	$7.79M	$8.80M	$6.70M	$5.33M	$12.32M	$7.73M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1698.35%	1436.99%	1.81%	0.97%	1.14%	1.42%	1.34%	1.14%	1.32%	1.41%	0.28%	-

MaxCyte's average Quarter SG&A projection for Dec 23 is $12.37M, based on 4 Wall Street analysts, with a range of $10.53M to $14.22M. The forecast indicates a -99.91% fall compared to MXCT last annual SG&A of $13.87B (Sep 23).

MaxCyte EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Jun 20	Mar 20
# Analysts	1	1	1	1	1	1	1	3	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	$-108.77	$-101.99	$-0.08	$-0.03	$-0.05	$-0.08	$-0.04	$-0.05	$-0.03	$-0.05	$-0.05	-
Avg Forecast	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.11	$-0.12	$-0.12	$-0.12	$-0.13	$-0.06	$-0.10	$-0.10	$-0.11	$-0.08	$-0.09	$-0.08	$-0.07	$-0.06	$-0.06	$-0.07	-	-
High Forecast	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.09	$-0.10	$-0.11	$-0.10	$-0.12	$-0.12	$-0.12	$-0.06	$-0.10	$-0.09	$-0.11	$-0.07	$-0.09	$-0.08	$-0.07	$-0.06	$-0.06	$-0.07	-	-
Low Forecast	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.11	$-0.11	$-0.13	$-0.12	$-0.13	$-0.13	$-0.07	$-0.10	$-0.10	$-0.12	$-0.08	$-0.09	$-0.08	$-0.07	$-0.06	$-0.06	$-0.07	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	1077.68%	1062.40%	0.75%	0.36%	0.56%	1.01%	0.59%	0.83%	0.52%	0.74%	-	-

According to undefined Wall Street analysts, MaxCyte's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MXCT previous annual EPS of $NaN (undefined).

MaxCyte Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
RPID	Rapid Micro Biosystems	$1.18	$8.00	577.97%	Hold
SGHT	Sight Sciences	$3.98	$9.00	126.13%	Hold
MXCT	MaxCyte	$3.55	$8.00	125.35%	Buy
LUNG	Pulmonx	$6.72	$11.93	77.53%	Buy
KIDS	OrthoPediatrics	$24.26	$39.60	63.23%	Buy
NPCE	NeuroPace	$9.15	$12.88	40.77%	Buy
OFIX	Orthofix Medical	$18.64	$24.00	28.76%	-
CNMD	CONMED	$75.65	$96.00	26.90%	Buy
CVRX	CVRx	$14.20	$16.33	15.00%	Buy
IRMD	IRadimed	$55.45	$60.00	8.21%	Buy
SRDX	Surmodics	$38.17	$39.50	3.48%	Buy
ITGR	Integer	$137.56	$138.00	0.32%	Buy

MXCT Forecast FAQ

Is MaxCyte a good buy?

Yes, according to 3 Wall Street analysts, MaxCyte (MXCT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of MXCT's total ratings.

What is MXCT's price target?

MaxCyte (MXCT) average price target is $8 with a range of $8 to $8, implying a 125.35% from its last price of $3.55. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will MaxCyte stock go up soon?

According to Wall Street analysts' prediction for MXCT stock, the company can go up by 125.35% (from the last price of $3.55 to the average price target of $8), up by 125.35% based on the highest stock price target, and up by 125.35% based on the lowest stock price target.

Can MaxCyte stock reach $5?

MXCT's average twelve months analyst stock price target of $8 supports the claim that MaxCyte can reach $5 in the near future.

What are MaxCyte's analysts' financial forecasts?

MaxCyte's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $45.01M (high $46.3M, low $43.61M), average EBITDA is $-25.887M (high $-25.081M, low $-26.626M), average net income is $-43.095M (high $-41.351M, low $-44.697M), average SG&A $41.44M (high $42.62M, low $40.15M), and average EPS is $-0.41 (high $-0.393, low $-0.425). MXCT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $55.55M (high $57.13M, low $53.82M), average EBITDA is $-31.944M (high $-30.95M, low $-32.857M), average net income is $-42.044M (high $-40.343M, low $-43.608M), average SG&A $51.13M (high $52.59M, low $49.54M), and average EPS is $-0.4 (high $-0.384, low $-0.415).

Did the MXCT's actual financial results beat the analysts' financial forecasts?

Based on MaxCyte's last annual report (Dec 2023), the company's revenue was $41.29M, beating the average analysts forecast of $41.24M by 0.11%. Apple's EBITDA was $-40.329M, beating the average prediction of $-23.719M by 70.03%. The company's net income was $-37.923M, missing the average estimation of $-39.15M by -3.13%. Apple's SG&A was $57.04M, beating the average forecast of $37.97M by 50.24%. Lastly, the company's EPS was $-0.0004, missing the average prediction of $-0.372 by -99.89%. In terms of the last quarterly report (Dec 2023), MaxCyte's revenue was $15.66M, beating the average analysts' forecast of $13.44M by 16.53%. The company's EBITDA was $15.66M, missing the average prediction of $-7.731M by -302.63%. MaxCyte's net income was $0, missing the average estimation of $-6.678M by -100.00%. The company's SG&A was $0, missing the average forecast of $12.37M by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $-0.0635 by -100.00%